Benchmarking empirical severity for the Yale-Brown Obsessive Compulsive Scale-Second Edition

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is the standard tool for assessing OCD severity. However, the updated Y-BOCS-II was developed to improve the measurement of severe symptoms and fix ceiling effects found in the original instrument. While clinicians have used benchmarks for years to interpret scores, empirical validation for the Y-BOCS-II scale had not yet been established. This research aimed to provide these benchmarks using a large, diverse, international sample of 2,982 children and adults across 13 countries.

The researchers used receiver-operating characteristic (ROC) analyses to determine the optimal cutoff points for the Y-BOCS-II, using the Clinical Global Impression-Severity (CGI-S) scale as the criterion for truth. They categorized individuals based on clinician ratings of overall psychopathology. The study leveraged a massive, multinational sample and tested the derived benchmarks in both a holdout portion of the main sample and an independent group of 78 patients from China to ensure the findings were robust and not just a result of specific local testing conditions.

The findings offer clear, evidence-based cutoffs for clinicians and researchers. The low-end severity benchmarks (non-/sub-clinical and mild) were largely consistent with those established for the original Y-BOCS. However, the moderate and severe ranges were shifted upward. Because the Y-BOCS-II has a higher maximum score than the original, the moderate range now extends up to 34 points, and the severe range begins at 35. These results were stable across different age groups and sexes, suggesting broad applicability across common clinical populations.

Having consistent, empirically derived benchmarks is essential for clinical trials and treatment monitoring. It allows researchers to interpret whether an intervention has moved a patient from one severity bracket to another in a meaningful way. This study resolves the ambiguity caused by the instrument's increased scale range, providing a standard reference that aligns with real-world clinical presentations.